Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced that it has entered into a distribution agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), to offer FDA-cleared ViaVerte™ — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Merit Medical launches Resilience TTS Esophageal Stent to address clinical gaps and expand its endoscopy portfolio with an advanced anti-migration design.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

MMSI rides strong cardiovascular demand and fast-growing therapeutic devices, but tariffs, OEM weakness and China macro pressures cloud the outlook.